expert column
within the drug development process.
The industry has seen a lot of innovation
in the application of technology and
will continue to do so. India is well
positioned to take advantage of these
trends given the rich technical expertise
that resides in this country.
Outlook is bright!
I believe that the worst is now behind
us. We have had a very challenging few
years but in the last couple of years,
several corrections have been made in
regulations to ensure it is more balanced
38
BioVoiceNews | June 2017
and science-oriented, while being
patient-centric. Our biggest challenge
now is to take that message globally
and restore the confidence of global
stakeholders in doing clinical research
in India. We have definitely seen an
improvement in regulatory approval
timelines and a more collaborative
and consultative approach by the
Indian regulators which is good for all
stakeholders. We are hopeful that this
forward momentum will continue.
We have seen a lot of streamlining
in the regulatory environment. We